Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

News > Western France

Please find below news from Western France, Basse Normandie, Bretagne, Pays de la Loire, Poitou-Charentes, Haute-Normadie, as well as about organisations from this region.

Total search results: 92 | Ordered by Date (descending)

order ascendingorder descendingSource order ascendingorder descendingDate
Theranexus S.A.. (4/9/19). "Press Release: Theranexus Announces Research Collaboration with IRISA Using Artificial Intelligence Technologies to Enhance Therapeutic Targeting of Neurological Interactions". Lyon. 2019-04-09
OSE Immunotherapeutics S.A.. (2/7/19). "Press Release: OSE Immunotherapeutics and Servier Announce First Option within Global License Agreement Exercised for further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases". 2019-02-07
Valneva S.E.. (1/7/19). "Press Release: Valneva Announces Its Intention to Delist from the Vienna Stock Exchange. Trading Will Be Centralized on Euronext Paris". Saint-Herblain. 2019-01-07
Valneva S.E.. (1/7/19). "Press Release: Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate". Saint-Herblain. 2019-01-07
Valneva S.E.. (12/21/18). "Press Release: Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate". Saint-Herblain. 2018-12-21
Valneva S.E.. (12/17/18). "Press Release: Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate". Saint-Herblain. 2018-12-17
Valneva S.E.. (12/6/18). "Press Release: Valneva and Hookipa Sign a Collaboration and Manufacturing Agreement". Saint-Herblain & Vienna. 2018-12-06
Valneva S.E.. (9/27/18). "Press Release: Valneva Raises €50 Million in Oversubscribed Placement Led by US Healthcare Investors [Not for Distribution in the United States, Canada, Australia or Japan]". Saint-Herblain. 2018-09-27
Valneva S.E.. (9/26/18). "Press Release: Valneva Launches a Capital Increase of Approximately €40 Million [Not for Distribution in the United States, Canada, Australia or Japan]". Saint-Herblain. 2018-09-26
Valneva S.E.. (9/20/18). "Press Release: Valneva Announces Extension of Drawdown Period for Its Existing European Investment Bank Loan". Saint-Herblain. 2018-09-20
SenzaGen AB. (7/16/18). "Press Release: SenzaGen Signs Distribution Agreement with the French Test Laboratory Eurosafe". Lund. 2018-07-16
Eurofins Scientific. (4/4/18). "Press Release: Eurofins Expands Its Offering in Radioactivity and Environmental Testing for the Nuclear Industry with the Acquisition of Eichrom Laboratoires in France". 2018-04-04
Boehringer Ingelheim. (4/4/18). "Press Release: Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors". Ingelheim & Nantes. 2018-04-04
Valneva S.E.. (2/26/18). "Press Release: Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate against Zika Virus". Gaithersburg, MD & Lyon. 2018-02-26
Valneva S.E.. (11/9/17). "Press Release: Valneva Reports Strong Operational Performance for the First Nine Months of 2017". Lyon. 2017-11-09
Valneva S.E.. (11/7/17). "Press Release: Valneva Signs $39.6 Million Ixiaro Supply Contract with US Government". Lyon. 2017-11-07
OSE Immunotherapeutics S.A.. (9/7/17). "Press Release: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio". Nantes. 2017-09-07
Valneva S.E.. (8/1/17). "Press Release: Valneva Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth". Lyon. 2017-08-01
Valneva S.E.. (7/24/17). "Press Release: Valneva Receives FDA Fast Track Designation for Its Lyme Disease Vaccine Candidate VLA15". Lyon. 2017-07-24
OSE Immunotherapeutics S.A.. (7/19/17). "Press Release: OSE Immunotherapeutics Receives €9.2 Million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)". Nantes. 2017-07-19
Genfit S.A.. (6/23/17). "Press Release: Genfit Reaches a Critical Milestone towards the Development of a Non-invasive In Vitro Diagnostic (IVD) Test for NASH". Lille & Cambridge, MA. 2017-06-23
Biophytis S.A.. (6/15/17). "Press Release: Biophytis Selects SGS Life Science Services to Conduct MACA-PK, Clinical Study of Macuneos in Dry AMD". Paris. 2017-06-15
Selexis S.A.. (5/23/17). "Press Release: Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist". Geneva & Nantes. 2017-05-23
Hookipa Biotech AG. (4/19/17). "Press Release: Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech". Vienna. 2017-04-19
Eurofins Scientific. (3/21/17). "Press Release: Eurofins and USP Announce Collaboration to Tackle Food Fraud". 2017-03-21
Valneva S.E.. (2/23/17). "Press Release: Valneva Reports Strong Q4 and FY 2016 Business Performance, Expects Further Growth in Sales and EBITDA, R&D Progress in 2017". Lyon. 2017-02-23
OSE Immunotherapeutics S.A.. (2/7/17). "Press Release: OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference New York February 13-14, 2017". Nantes. 2017-02-07
IntegraGen S.A.. (2/3/17). "Press Release: IntegraGen Announces Successful Completion of a € 3.7 Million Capital Increase". Évry. 2017-02-03
McDermott Will & Emery. (1/6/17). "Press Release: McDermott Will & Emery Advised Servier in Its License Option Agreement with OSE Immunotherapeutics". Paris. 2017-01-06
Valneva S.E.. (1/5/17). "Press Release: Valneva Announces a New Research License Agreement with MSD Animal Health for the Development of Vaccines in the EB66 Cell Line". Lyon. 2017-01-05
OSE Immunotherapeutics S.A.. (12/28/16). "Press Release: OSE Immunotherapeutics Signs a License Option Agreement with Servier to Develop and Commercialize the Product Effi-7". Nantes & Paris. 2016-12-28
Valneva S.E.. (12/15/16). "Press Release: Valneva Confirms Closing of Private Placement in Connection with €15.2m Investment by MVM Life Science Partners". Lyon. 2016-12-15
TxCell S.A.. (12/8/16). "Press Release: TxCell Signs In-licensing Global Agreement with Inserm Transfert for Novel Population of Regulatory T Cells". Valbonne & Nantes. 2016-12-08
Valneva S.E.. (12/1/16). "Press Release: Leading Healthcare Investor MVM Life Science Partners Acquires 7.5% Shareholding in Valneva". Lyon. 2016-12-01
OSE Immunotherapeutics S.A.. (11/15/16). "Press Release: Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases". Geneva & Nantes. 2016-11-15
Valneva S.E.. (11/9/16). "Press Release: Valneva Reports Strong Business Performance in First Nine Months, Company Increases Financial Guidance for Full Year 2016". Lyon. 2016-11-09
Bruker Corporation. (10/6/16). "Press Release: Bruker Introduces Enhanced Wine-Profiling Module 3.1 for its NMR FoodScreener". Billerica, MA. 2016-10-06
Valneva S.E.. (7/12/16). "Press Release: European Investment Bank Grants Valneva a €25 Million Loan to Fund R&D Activities". Lyon & Luxembourg. 2016-07-12
OSE Immunotherapeutics S.A.. (7/5/16). "Press Release: OSE Immunotherapeutics Announces Exercise of Option within Global License Agreement with Janssen for Further Clinical Development of FR104 and Potential Commercialisation in Autoimmune Diseases". Par 2016-07-05
Qiagen N.V.. (6/2/16). "Press Release: Qiagen Forms Lung Cancer Expert Alliance. Key Opinion Leaders’ Expertise to Guide Design of New Gene Panels for GeneReader NGS". Hilden & Germantown, MD. 2016-06-02
OSE Pharma S.A.. (4/15/16). "Press Release: OSE Pharma and Effimune Announce the Signing of the Merger Treaty to Create OSE Immunotherapeutics". Paris & Nantes. 2016-04-15
OSE Pharma S.A.. (3/21/16). "Press Release: 2015 Annual Results in Line with Forecasts, and Significant Clinical Advances. 2016 Outlook – Further Development and Merger Project with Effimune". Paris. 2016-03-21
Valneva S.E.. (2/24/16). "Press Release: Valneva Posts 96% Revenue Growth in 2015, Forecasts 2016 Revenues of €90 to €100 Million". Lyon. 2016-02-24
OSE Pharma S.A.. (2/24/16). "Press Release: OSE Pharma and Effimune Announce Proposed Merger to Create Significant Immunotherapy Player". Paris & Nantes. 2016-02-24
Valneva S.E.. (11/10/15). "Press Release: Valneva Reports a Strong Quarter Marked by Key Successes in its Strategic Execution and a Solid Financial Performance". Lyon. 2015-11-10
Pherecydes Pharma. (9/9/15). "Press Release: A World First. Pherecydes Pharma Launches Multicenter Clinical Study of Phage Therapy in Serious Burn Victims". Romainville. 2015-09-09
Valneva S.E.. (8/27/15). "Press Release: Valneva Announces Two New EB66 Agreements. 7 new EB66 Deals Signed Since the Beginning of the Year". Lyon. 2015-08-27
Valneva S.E.. (7/23/15). "Press Release: Valneva and PaxVax Enter into Marketing and Distribution Agreement". Lyon. 2015-07-23
Valneva S.E.. (6/22/15). "Press Release: Valneva Takes Direct Control Over Marketing and Distribution of Ixiaro to Increase Margin and Profitability ". Lyon. 2015-06-22
Eurofins Scientific. (6/10/15). "Press Release: Eurofins Launches an Innovative DNA Chip Technology Enabling the Identification of 21 Animal Species in Food and Feed". 2015-06-10
Advanced Chemistry Development, Inc. (ACD/Labs). (5/19/15). "Press Release: Increased Multi-technique Analytical Efficiency in an Academic Environment. Streamlining Analytical Data Interpretations at the University of Angers". Angers. 2015-05-19
Valneva S.E.. (3/26/15). "Press Release: Valneva Announces Approval of an EB66-based Prototype Influenza Vaccine in Japan". Lyon. 2015-03-26
PPF Group N.V.. (2/4/15). "Press Release: PPF Group Acquires a Minority Stake in Biotech Company Cytune Pharma in Cooperation with Sotio". 2015-02-04
Valneva S.E.. (2/4/15). "Press Release: Valneva Announces the Successful Completion of Its EUR 45 Million Capital Increase [Not for United States, Canada, Australia or Japan]". Lyon. 2015-02-04
Valneva S.E.. (1/29/15). "Press Release: Valneva Grants Exclusive Worldwide License to Immune Targeting Systems for the Development of Hepatitis B Vaccines in Combination with the IC31 Adjuvant". Lyon. 2015-01-29
Carlina Technologies. (12/16/14). "Press Release: Carlina Technologies Signs a Partnership Agreement with Atlangram to Develop Controlled-release Forms of Antibiotics Targeting Osteoarticular Diseases". Angers. 2014-12-16
Valneva S.E.. (12/11/14). "Press Release: Valneva and BliNK Therapeutics Announce Launch of New Biotech Company in Innovative Antibody Discovery. New company Has Already Secured First Round of Financing". Louvain-la-Neuve. 2014-12-11
Valneva S.E.. (12/10/14). "Press Release: Valneva Announces Publication of First Phase II Data of Tuberculosis Vaccine Candidate Formulated with IC31® Adjuvant. Clinical Trial in HIV-infected Adults Showed Good Safety and Immunogenicity". Lyon. 2014-12-10
Valneva S.E.. (11/6/14). "Press Release: Valneva Announces Best Quarterly Results Since Vivalis/Intercell Merger, Meets Business Objectives amd Reconfirms Full Year Outlook". Lyon. 2014-11-06
Carlina Technologies. (11/4/14). "Press Release: Carlina Technologies Signs a Partnership Agreement with Genbiotech to Develop a Sustained-release Protein Formulation for Cartilage Repair". Angers. 2014-11-04
Valneva S.E.. (8/8/14). "Press Release: Valneva Reports H1 2014 Results, Confirms Full Year Outlook, and Provides Business Update". Lyon. 2014-08-08
Symrise AG. (4/12/14). "Press Release: Acquisition of Diana Group – Symrise Gearing Up for Second Decade of Acclerated Growth". 2014-04-12
Valneva S.E.. (3/24/14). "Press Release: Valneva Announces Continuation of the Phase II/III Clinical Trial for Its Pseudomonas Aeurginosa Vaccine Candidate". Lyon. 2014-03-24
Valneva S.E.. (3/24/14). "Press Release: Valneva Reports Annual Results 2013. Company Sees First Year of Merger as Operational and Human Success". Lyon. 2014-03-24
Valneva S.E.. (11/5/13). "Press Release: Valneva Records Highest Ixiaro/Jespect Sales in Q3 2013, Confirms Full Year Outlook, and Provides R&D Update for Pseudomonas Vaccine Candidate". Lyon. 2013-11-05
Effimune S.A.S.. (10/3/13). "Press Release: Effimune Announces Global License Agreement with Janssen". Nantes. 2013-10-03
Valneva S.E.. (8/12/13). "Press Release: Valneva Announces Passing of Management Board Member, Chief Scientific Officer Majid Mehtali". Lyon. 2013-08-12
bioMérieux S.A.. (7/18/13). "Press Release: First-half 2013 Business Review". Marcy l’Étoile. 2013-07-18
Valneva S.E.. (7/16/13). "Press Release: Valneva Announces a New EB66 Cell Line Research License Agreement with Boehringer Ingelheim". Lyon. 2013-07-16
Valneva S.E.. (7/4/13). "Press Release: Valneva Announces the Successful Completion of Its €40 Million Capital Increase – Transaction Was Oversubscribed by 146% [Not for US, Canada, Australia, or Japan]". Lyon. 2013-07-04
Vivalis S.A.. (4/8/13). "Press Release: Vivalis Announces a New EB66 Cell Line Research Services and License Option Agreement with GlaxoSmithKline". 2013-04-08
Vivalis S.A.. (3/26/13). "Press Release: Consolidated 2012 Financial Results". Nantes & Lyon. 2013-03-26
Vivalis S.A.. (3/26/13). "Press Release: The Expanded Development of EB66 Cell Line as Part of the GlaxoSmithKline (GSK) – Texas A&M University System Influenza Vaccine Program in the United States". Nantes & Lyon. 2013-03-26
Agilent Technologies Inc.. (3/11/13). "Press Release: Agilent Technologies to Host Webinars on Food Safety and Quality. Focus Will Be on GC/MS, LC/MS, IPC-MS Measurement Solutions". Santa Clara, CA. 2013-03-11
Vivalis S.A.. (3/7/13). "Press Release: Vivalis SA and Intercell AG Shareholders Approved the Proposed Merger of Equals to Create Valneva SE". Nantes & Vienna. 2013-03-07
Intercell AG. (3/5/13). "Press Release: Q4 Report 2012. Intercell AG Announces Q4 and Preliminary Full Year 2012 Financial Results and Business Update". Vienna. 2013-03-05
Vivalis S.A.. (2/14/13). "Press Release: 2012 – A Record Year for New EB66 Cell Line Licensing". Nantes. 2013-02-14
Vivalis S.A.. (12/16/12). "Press Release: Proposed Merger of Equals between Vivalis and Intercell. Creation of a European Biotech Leader in Vaccines and Antibodies [Not for Distribution in Australia, Canada, Japan or the United States]". Nantes & Vienna. 2012-12-16
bioMérieux S.A.. (10/23/12). "Press Release: Business Review for the Nine Months Ended September 30, 2012". Marcy l’Étoile. 2012-10-23
Vivalis S.A.. (8/28/12). "Press Release: Vivalis Announces a New EB66 Cell Line Research License Agreement with BioFactura". Nantes & Lyon. 2012-08-28
Vivalis S.A.. (8/21/12). "Press Release: Successful Growth of BioDiem’s Virus in Vivalis EB66 Cell Line". Melbourne & Nantes. 2012-08-21
Vivalis S.A.. (6/20/12). "Press Release: Vivalis Announces a New EB66 Cell Line Commercial License Agreement with Farvet Farmacológicos Veterinarios". 2012-06-20
Vivalis S.A.. (3/29/12). "Press Release: Vivalis 2011 Results. Continuing Growth Momentum". Nantes & Lyon. 2012-03-29
Vivalis S.A.. (3/13/12). "Press Release: Vivalis Announces the Signature of a Broad Collaboration Agreement and Commercial License for the Use of the EB66 Cell Line for the Production of a Monoclonal Antibody". Nantes & Lyon. 2012-03-13
Vivalis S.A.. (1/24/12). "Press Release: Strong Revenue Growth – +112%. Initation of a Third Antibody Discovery Program with Sanofi Pasteur". Nantes & Lyon. 2012-01-24
Vivalis S.A.. (1/23/12). "Press Release: Opening of a New Laboratory Dedicated to the Viva|Screen Antibody Discovery Platform". Nantes, Lyon & Toyama. 2012-01-23
Vivalis S.A.. (1/17/12). "Press Release: Vivalis and Sanofi Pasteur Extend Their 2010 Collaboration and License Contract with a New Human Monoclonal Antibody Discovery Target against a New Infectious Disease". Nantes, Lyon & Toyama. 2012-01-17
Eurofins Scientific. (9/23/11). "Press Release: Eurofins Announces the Inauguration of Its Nantes Laboratory Extension Turning into the Largest Single-site Independent Food Testing Laboratory in the World". 2011-09-23
bioMérieux S.A.. (5/19/11). "Press Release: bioMérieux Becomes the World Leader in Food Testing with AES Laboratoire Acquisition". Marcy l’Étoile. 2011-05-19
Cerep S.A.. (1/18/11). "Press Release: Cerep to Reorganize Its Operations in France". Paris. 2011-01-18
SGS S.A.. (11/15/10). "Press Release: SGS’s Life Sciences Services Plans Expansion of Its Biopharmaceutical and Bioanalytical Testing Services Business in Its Poitiers, France Facility". 2010-11-15
Vivalis S.A.. (1/11/10). "Press Release: Vivalis Announces the Strategic Acquisition of Humalys and the Addition of a New Platform for Generating Human Monoclonal Antibodies". Nantes. 2010-01-11




Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top